← Eichor
Condition: Waldenstroms Macroglobulinaemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Waldenstroms Macroglobulinaemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00923507Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · C. Babis Andreadis · NCT04545762Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Z
Phase 2 · 136 location(s) · National Cancer Institute (NCI) · NCT04840602Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractor
Phase 2 · 17 location(s) · AbbVie · NCT07387471Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT0686088064Cu-LLP2A for Imaging Hematologic Malignancies
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06636175Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk
Phase 2 · 1 location(s) · Emory University · NCT04883437Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Phase 2 · 121 location(s) · Merck Sharp & Dohme LLC · NCT04728893A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacyti
Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT07231952Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/Phase 2 · 2 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT07249905Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.